Breast cancer with HER2 overexpression is defined by immunohistochemistry status (IHC3+) or fluorescence in-situ hybridization (FISH) measurement of a HER2 gene copy number above six or a HER2/CEP17 ratio equals or greater than two (2). The gene discussed is ERBB2; the disease is breast cancer.